Atlantic Coastal Acquisition Corp. II financial data

Symbol
ACAB, ACABU, ACABW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6 St Johns Lane, Floor 5, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - Jul 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 62.2 % +53.8%
Debt-to-equity -153 % -35.7%
Return On Equity 1.9 %
Return On Assets -0.99 % -177%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 0 USD

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -2.27M USD -8.36%
Nonoperating Income (Expense) 2.47M USD -67.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 204K USD -96.3%
Income Tax Expense (Benefit) 502K USD -66.6%
Net Income (Loss) Attributable to Parent -298K USD -107%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.6K USD -96.4%
Assets, Current 25.8K USD -95.5%
Assets 7.53M USD -97.6%
Accrued Liabilities, Current 469K USD -62.3%
Liabilities, Current 6.61M USD +109%
Liabilities 17.1M USD +25.2%
Retained Earnings (Accumulated Deficit) -17M USD -45.6%
Stockholders' Equity Attributable to Parent -17M USD -45.6%
Liabilities and Equity 7.53M USD -97.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -264K USD -171%
Net Cash Provided by (Used in) Financing Activities -29.7M USD
Net Cash Provided by (Used in) Investing Activities 29.7M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -254K USD -161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.6K USD -96.4%
Deferred Tax Assets, Valuation Allowance 687K USD +76.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Cash and Cash Equivalents, Period Increase (Decrease) 331K USD
Deferred Tax Assets, Gross 687K USD +76.8%
Deferred Tax Assets, Operating Loss Carryforwards 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%